{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:00Z","timestamp":1787019600017,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Asparaginase-associated toxicities (AAT) often compromise therapy for acute lymphoblastic leukemia (ALL), affecting relapse risk and survival. There are conflicting data on the contributions of older age, obesity by body mass index (BMI), and\/or large body surface area (BSA) to AAT. We examined the association of these risk factors with AAT and the impact of AAT on disease response. Induction data were examined from 4925 patients aged between 1 and 30 years enrolled in the Children\u2019s Oncology Group ALL trials AALL0232 and AALL0434, which included a single dose of pegaspargase (2500 IU\/m2) without a maximum dose. The associations of age, BMI, and BSA with hyperbilirubinemia, elevated alanine aminotransferase (ALT), thrombosis, and pancreatitis were evaluated. The impact of AAT on minimal residual disease (MRD) positivity (\u22650.01%) at the end of induction (EOI) was assessed. Increased risk of developing at least 1 AAT was observed in patients aged \u226510 years (P = .002) and in those with obesity and high BSA (P&amp;lt; .0001) but not with high BSA alone. Risks for hyperbilirubinemia, ALT elevations, and thrombosis were all increased in patients with obesity and high BSA (odds ratio [OR], 3.5; 95% confidence interval [CI], 2.2-5.7; OR, 3.3; 95% CI, 1.7-6.6; and OR, 3.1; 95% CI, 1.5-6.5, respectively). AAT were not associated with EOI MRD positivity. To our knowledge, we report the largest data set of AAT in children, adolescents, and young adults. Preventive strategies are indicated for older patients and for those with obesity and high BSA, but not with high BSA alone. These trials were registered at www.clinicaltrials.gov as NCT00075725 and NCT00408005.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019870","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:54:38Z","timestamp":1778010878000},"page":"4923-4930","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children\u2019s Oncology Group"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-6818","authenticated-orcid":false,"given":"Etan","family":"Orgel","sequence":"first","affiliation":[{"name":"1Cancer and Blood Disease Institute, Children\u2019s Hospital Los Angeles, Los Angeles, CA"},{"name":"2Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke D.","family":"Maese","sequence":"additional","affiliation":[{"name":"3Huntsman Cancer Institute, Primary Children\u2019s Hospital, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-3478","authenticated-orcid":false,"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[{"name":"4St Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Militano","sequence":"additional","affiliation":[{"name":"5Children\u2019s Oncology Group, Arcadia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-6603","authenticated-orcid":false,"given":"Rachel E.","family":"Rau","sequence":"additional","affiliation":[{"name":"6Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children\u2019s Research Institute, Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington, Seattle, WA"},{"name":"7Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"8Center for Cancer and Blood Disorders, Children\u2019s National Hospital, Washington, DC"},{"name":"9Department of Pediatrics and Clinical and Translational Oncology Program, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"McNeer","sequence":"additional","affiliation":[{"name":"3Huntsman Cancer Institute, Primary Children\u2019s Hospital, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-2168","authenticated-orcid":false,"given":"Reuven J.","family":"Schore","sequence":"additional","affiliation":[{"name":"8Center for Cancer and Blood Disorders, Children\u2019s National Hospital, Washington, DC"},{"name":"9Department of Pediatrics and Clinical and Translational Oncology Program, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"10Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-3969","authenticated-orcid":false,"given":"Brent","family":"Wood","sequence":"additional","affiliation":[{"name":"2Keck School of Medicine, University of Southern California, Los Angeles, CA"},{"name":"11Department of Pathology and Laboratory Medicine, Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Raetz","sequence":"additional","affiliation":[{"name":"12Perlmutter Cancer Center, Division of Pediatric Hematology and Oncology, Department of Pediatrics, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7275-7650","authenticated-orcid":false,"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"13Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6636-3870","authenticated-orcid":false,"given":"Naomi J.","family":"Winick","sequence":"additional","affiliation":[{"name":"14University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Larsen","sequence":"additional","affiliation":[{"name":"15Maine Children\u2019s Cancer Program, Scarborough, ME"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Carroll","sequence":"additional","affiliation":[{"name":"11Department of Pathology and Laboratory Medicine, Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart S.","family":"Winter","sequence":"additional","affiliation":[{"name":"16Cancer and Blood Disorders Program, Children\u2019s Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley P.","family":"Dunsmore","sequence":"additional","affiliation":[{"name":"17Virginia Tech University, Roanoke, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-3957","authenticated-orcid":false,"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics and Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4099-4700","authenticated-orcid":false,"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"6Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children\u2019s Research Institute, Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington, Seattle, WA"},{"name":"7Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"2","key":"2026072809373533700_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0976-500X.184769","article-title":"L-asparaginase in the treatment of patients with acute lymphoblastic leukemia","volume":"7","author":"Egler","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"issue":"2","key":"2026072809373533700_bib2","first-page":"535","article-title":"L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia","volume":"37","author":"Ortega","year":"1977","journal-title":"Cancer Res"},{"issue":"3","key":"2026072809373533700_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"issue":"28","key":"2026072809373533700_bib4","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026072809373533700_bib5","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"issue":"14","key":"2026072809373533700_bib6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2026072809373533700_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.clml.2021.07.009","article-title":"SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia","volume":"21","author":"Schmiegelow","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2026072809373533700_bib8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"2026072809373533700_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MPH.0000000000000589","article-title":"A pilot study of intensified PEG-asparaginase in high-risk acute lymphoblastic leukemia: Children's Oncology Group study AALL08P1","volume":"38","author":"Rodriguez","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2026072809373533700_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"2026072809373533700_bib11","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026072809373533700_bib12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2026072809373533700_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2026072809373533700_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/bloodadvances.2022007791","article-title":"The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study","volume":"7","author":"Aldoss","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"2026072809373533700_bib15","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020006583","article-title":"Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia","volume":"137","author":"Gottschalk H\u00f8jfeldt","year":"2021","journal-title":"Blood"},{"issue":"21","key":"2026072809373533700_bib16","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/cam4.4281","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia","volume":"10","author":"Schulte","year":"2021","journal-title":"Cancer Med"},{"issue":"18","key":"2026072809373533700_bib17","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1182\/bloodadvances.2023009976","article-title":"Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026072809373533700_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13046-022-02585-x","article-title":"Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL Study Group","volume":"42","author":"Junk","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2026072809373533700_bib19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/10428194.2017.1349902","article-title":"PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia","volume":"59","author":"Rausch","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2026072809373533700_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2018.02.150","article-title":"Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia","volume":"165","author":"Prasca","year":"2018","journal-title":"Thromb Res"},{"issue":"suppl 1","key":"2026072809373533700_bib21","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1182\/blood-2021-151313","article-title":"Impact of age, body surface area, and body mass index on pegaspargase toxicity and pharmacokinetics: a report from the DFCI ALL Consortium","volume":"138","author":"Paolino","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2026072809373533700_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age","volume":"38","author":"Rank","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026072809373533700_bib23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jth.13236","article-title":"Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study","volume":"14","author":"Tuckuviene","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2026072809373533700_bib24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pbc.21734","article-title":"Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer","volume":"51","author":"Athale","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2026072809373533700_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1078155217701291","article-title":"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen","volume":"24","author":"Christ","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"2026072809373533700_bib26","doi-asserted-by":"crossref","first-page":"e26555","DOI":"10.1002\/pbc.26555","article-title":"Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU","volume":"64","author":"Lebovic","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2026072809373533700_bib27","doi-asserted-by":"crossref","first-page":"n\/a","DOI":"10.1002\/pbc.26891","article-title":"Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens","volume":"65","author":"Denton","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"24","key":"2026072809373533700_bib28","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2014-11-551481","article-title":"How I treat acute lymphoblastic leukemia in older adolescents and young adults","volume":"125","author":"Curran","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026072809373533700_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1078155219838316","article-title":"Optimizing pegylated asparaginase use: an institutional guideline for dosing, monitoring, and management","volume":"26","author":"Bade","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2026072809373533700_bib30","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","volume":"11","author":"O'Brien","year":"2024","journal-title":"Lancet Haematol"},{"issue":"3","key":"2026072809373533700_bib31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2026072809373533700_bib32","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"2026072809373533700_bib33","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2026072809373533700_bib34","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.2023020678","article-title":"Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study","volume":"142","author":"Wood","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2026072809373533700_bib35","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"28","key":"2026072809373533700_bib36","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026072809373533700_bib37","first-page":"1","article-title":"CDC growth charts: United States","volume":"314","author":"Kuczmarski","year":"2000","journal-title":"Adv Data"},{"issue":"6","key":"2026072809373533700_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamapediatrics.2014.21","article-title":"Prevalence and trends in obesity and severe obesity among children in the United States, 1999-2012","volume":"168","author":"Skinner","year":"2014","journal-title":"JAMA Pediatr"},{"key":"2026072809373533700_bib39","unstructured":"National Comprehensive Cancer Network, Adolescent and Young Adult Oncology (Version 2.2026). Accessed 18 May 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aya.pdf."},{"key":"2026072809373533700_bib40","doi-asserted-by":"crossref","first-page":"902117","DOI":"10.3389\/fped.2022.902117","article-title":"Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"10","author":"Maese","year":"2022","journal-title":"Front Pediatr"},{"issue":"21","key":"2026072809373533700_bib41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood.V116.21.494.494","article-title":"PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for adult ALL (GMALL) study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2026072809373533700_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2026072809373533700_bib43","doi-asserted-by":"crossref","first-page":"e259952","DOI":"10.1001\/jamanetworkopen.2025.9952","article-title":"Overweight or obesity and outcomes in children with acute lymphoblastic leukemia","volume":"8","author":"Ladas","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026072809373533700_bib44","doi-asserted-by":"crossref","first-page":"e28063","DOI":"10.1002\/pbc.28063","article-title":"Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia","volume":"67","author":"Hashmi","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"18","key":"2026072809373533700_bib45","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1182\/bloodadvances.2025016160","article-title":"Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia","volume":"9","author":"Rodriguez","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026072809373533700_bib46","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/10781552231202217","article-title":"Impact of pegaspargase dose capping on incidence of pegaspargase-related adverse events in adults","volume":"30","author":"Tiao","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"2026072809373533700_bib47","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","article-title":"Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"61","author":"Derman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026072809373533700_bib48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026072809373533700_bib49","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/bloodadvances.2020004018","article-title":"Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial","volume":"5","author":"Orgel","year":"2021","journal-title":"Blood Adv"},{"issue":"34","key":"2026072809373533700_bib50","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"31","key":"2026072809373533700_bib51","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"S3","key":"2026072809373533700_bib52","first-page":"e31444","article-title":"A comparison of pegaspargase and calaspargase-pegol toxicity in high-risk B-acute lymphoblastic leukemia (B-ALL) induction and consolidation: a report from the Children's Oncology Group study AALL1732","volume":"71","author":"Maese","year":"2024","journal-title":"Pediatr Blood Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4923\/2533275\/blooda_adv-2026-019870-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4923\/2533275\/blooda_adv-2026-019870-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:37:49Z","timestamp":1785245869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/14\/4923\/568184\/Toxicity-from-asparaginase-during-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":52,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019870","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,28]]},"published":{"date-parts":[[2026,7,15]]}}}